Headache
Trigeminal Neuralgia
search
Trigeminal Neuralgia
, Tic Douloureux, Fothergill’s Disease
See Also
Trigeminal Nerve
Trigeminal Autonomic Cephalalgia
Cluster Headache
SUNCT Syndrome
Paroxysmal Hemicrania
Hemicrania Continua
History
John Fothergill first accurately described Trigeminal Neuralgia in 1773
Pearce (2003) J Neurol Neurosurg Psychiatry 74:1688 [PubMed]
Epidemiology
Incidence
: 15,000 new cases per year in U.S. (3.4 women or 5.9 men per 100,000 per year)
Incidence
in UK as high as 26.8 per 100,000, and 12.6 per 100,000 in Netherlands (but criteria vary)
Primary care physicians may see a few cases during their entire practice career
Incidence
in
Multiple Sclerosis
patients: 1-2%
Onset after age 40 years in 90% of cases
Mean age of onset 50 years old, with a peak at age 60 to 70 years
Incidence
increases to 45.2 per 100,000 in men over age 80 years old
More common in women by ratio of 2:1
Familial association in 1-2% of Trigeminal Neuralgia patients
Risk Factors
Cerebrovascular Accident
Hypertension
in women
Causes
Idiopathic
Space occupying lesions
Cerebral Arteriovenous Malformation
Multiple Sclerosis
(present in 2-4% of Trigeminal Neuralgia cases, RR 20)
Consider in younger patients (20-30 years old), especially with other neurologic involvement
Outside of
Multiple Sclerosis
, Trigeminal Neuralgia is typically a condition of older patients (see above)
Pathophysiology
Most often primary TN (classic) or idiopathic, but may be secondary to other causes (e.g. MS, CVA)
Related to
Trigeminal Nerve
demyelination
Demyelination due to compression from local structures (esp.
Superior Cerebellar Artery
)
Narrow foramen ovale may also contribute
Demyelinated fibers are hyperactive, sending ectopic impulses with altered transmission
Demyelinated fibers are more prone to ephaptic conduction
Light touch impulses transmit to nearby pain fibers
Most common site at cerebellopontine nerve root area
Effects all branches of the
Trigeminal Nerve
(Right side is more commonly involved)
Maxilla
ry branch is most commonly involved
Ophthalmic branch is least commonly involved
Symptoms
Facial pain in
Trigeminal Nerve
distribution
Recurrent paroxysms of sharp, stabbing or lancinating pain
Distribution
Maxilla
ry and mandibular branches of the
Trigeminal Nerve
(
CN 5
) are most commonly affected
Each attack is unilateral (may alternate sides in up to 3-5% of cases)
Characteristics
Lancinating or stabbing pain that is severe and intense
Electric shock type pain
Facial spasms related to paroxysms of pain (Tic Douloureux) may occur
Timing
Each attack lasts for seconds to minutes
Attacks may occur as often as multiple times daily (as many as 100/day) or as infrequently as monthly
Attacks become more frequent and severe over time (and more refractory to medication)
Attacks are rare during sleep
Remissions of more than 6 months occur in 50% of patients
Triggers
Washing face
Tooth Brush
ing
Cold exposure
Chewing
Trigger Zone
s (pathognomonic for Trigeminal Neuralgia)
Small areas in the region of the nose and mouth
Light touch or other minimal stimulation in these zones triggers an attack
Associated Findings
Autonomic findings (
Lacrimation
,
Eye Redness
) may occur with paroxysmal pain episodes
History
Red Flags suggesting secondary cause or alternative diagnosis
Abnormal findings on
Neurologic Exam
ination (e.g. intracranial lesion)
Abnormal findings on examination of head and neck (e.g. dental or ear-related source)
Age under 40 years old
Severe, lancinating paroxysmal pain episode lasts longer than 2 minutes
Pain outside the
Trigeminal Nerve
distribution
Bilateral pain during a single attack
Different attacks may affect other side in 3% of patients
Vision
change,
Hearing
change or
Vertigo
Numbness
Findings suggestive of
Multiple Sclerosis
(e.g.
Ataxia
, unilateral
Vision
change)
Multiple Sclerosis
is often comorbid with Trigeminal Neuralgia
Examination
Evaluate for focal findings suggestive of a secondary cause or alternative diagnosis
Specific focal areas of examination (abnormalities suggest alternative diagnosis)
Temporomandibular Joint
Facial
Muscle Strength
and symmetry
Corneal Reflex
Trigeminal Nerve
Sensation
(normal in Trigeminal Neuralgia)
Trigger Zone
presence is pathognomonic for Trigeminal Neuralgia (see above)
Diagnosis
Classic Trigeminal Neuralgia (ICHD3 Criteria)
Recurrent paroxysms of unilateral facial pain
Follows distribution of one or more
Trigeminal Nerve
and no radiation beyond
Pain meets all 3 criteria
Painful paroxysms last <=2 minutes
Severe intensity
Electric shock-like shooting, stabbing or sharp pain
Triggered by innocuous stimuli in the affected trigeminal distribution (e.g.
Trigger Zone
s)
Not better accounted for by another ICHD-3 Diagnosis
Types
Trigeminal Neuralgia (ICHD3 Categories)
Classic (purely paroxysmal)
Recurrent attacks of unilateral facial pain meeting classic Trigeminal Neuralgia criteria (as above)
Pain-free in the affected trigeminal region between attacks
Classic with concomitant persistent facial pain
Recurrent attacks of unilateral facial pain meeting Trigeminal Neuralgia criteria (as above)
Continuous or near continuous pain in the affected trigeminal region between attacks
Aching, lower level pain persists between episodes
Secondary Trigeminal Neuralgia
Recurrent attacks of unilateral facial pain meeting Trigeminal Neuralgia criteria (paroxysmal or persistent)
Underlying causative condition identified
Not better attributed to another disorder
Idiopathic Trigeminal Neuralgia
Recurrent attacks of unilateral facial pain meeting Trigeminal Neuralgia criteria (paroxysmal or persistent)
Does not meet criteria for classic or for secondary after thorough investigation (e.g.
Brain MRI
, EMG)
Not better attributed to another disorder
Differential Diagnosis
Cluster Headache
or other
Migraine Headache
Postherpetic Neuralgia
Glossopharyngeal Neuralgia
Dental Infection
or
Dental Caries
Temporomandibular Joint Syndrome
Acoustic Neuroma
Multiple Sclerosis
(may be comorbid)
Vascular Malformation
Labs
No specific lab testing is indicated for Trigeminal Neuralgia (unless exploring differential diagnosis)
Imaging
Brain MRI
(with and without contrast) Indications
Indicated in most cases of Trigeminal Neuralgia at onset
Intracranial lesions are present in up to 10% of cases
Evaluate for other diagnoses (e.g. MS,
Cerebral Aneurysm
)
Identify surgical intervention opportunities (e.g. narrow foramen ovale)
Brain MRA and Neck MRA
Consider for evaluation of neurovascular compression and other findings (e.g.
AV Malformation
)
Diagnostics
Trigeminal reflex testing (via EMG testing)
Indicated in atypical presentations
Differentiates classic from secondary Trigeminal Neuralgia with high efficacy
Cruccu (2006) Neurology 66:139-41 [PubMed]
Management
Gene
ral
Neurology referral
Evaluate for comorbid conditions (
Multiple Sclerosis
, Intracranial Lesions)
Management
Antiepileptics (and othe neurologic agents)
Precautions
Agents are initially effective in 75% of patients
Efficacy wanes with time and symptoms may then worsen and become refractory
Mechanism
Seizure
medications stabilize
Neuron
membrane and decrease excitability and erratic pain signal transmission
Carbamazepine
(Most studied)
Dosing
Start 200 mg orally twice daily
Titrate as needed to effect over the course of weeks to 800 mg/day (typical effective dose)
Maximum daily dose: 1200 mg/day for Trigeminal Neuralgia
Efficacy
Initial excellent response rates >70% (NNT 2)
Longterm failure rate approches 50% after 5-10 years of continuous use
Oxcarbazepine
(
Trileptal
)
Dosing
Initial: 300 mg orally twice daily
Increase by 300 mg/day every 3 to 7 days
Typical effective dose 1200 mg/day divided twice daily
Maximum: 1800 mg/day for Trigeminal Neuralgia
Efficacy
Effective for pain reduction
Fewer side effects than
Carbamazepine
, but less effective in the longterm
Baclofen
(
Lioresal
)
Typical effective doses: 10-80 mg/day
Consider in
Multiple Sclerosis
patients with Trigeminal Neuralgia
Agents with unknown effectiveness (inadequate studies as of 2025)
Phenytoin
(
Dilantin
)
Gabapentin
(
Neurontin
)
Topiramate
(
Topamax
)
Sumatriptan
(
Imitrex
)
Lamotrigine
(
Lamictal
)
May worsen MS symptoms
References
Delzell (1999) Arch Fam Med 8(3): 264-8 [PubMed]
Management
Other Symptomatic Therapy
Topical
Capsaicin
Intranasal
Lidocaine
8%
Indicated for rescue therapy of acute Trigeminal Neuralgia exacerbations
Sprayed on the nasal and/or
Oral Mucosa
Blocks the sphenopalatine
Ganglion
(for second
Trigeminal Nerve
branch)
Zhou (2023) Cephalalgia 43(5):3331024231168086 +PMID: 37032614 [PubMed]
Onabotulinumtoxin A
(
Botox
)
May decrease intensity and frequency of attacks at 6 weeks to 3 months
Rubis (2020) J Oral Maxillofac Res 11(2): e2 [PubMed]
Transcutaneous electrical nerve stimulation
(
TENS
)
May decrease pain during flares
Motwani (2023) J Clin Exp Dent 15(6): e505-10 [PubMed]
Acupuncture
is ineffective in Trigeminal Neuralgia
Millan-Guerrero (2006) Headache 46(3): 532 [PubMed]
Management
Surgical Management
Indications for neurosurgery referral
Refractory Trigeminal Neuralgia (or when medications are poorly tolerated)
Secondary Trigeminal Neuralgia
Structural pathology (e.g. narrow foramen ovale) on imaging
Percutaneous Methods (non-invasive but short lasting)
Glycerol
injection
Gamma Knife
Stereotactic Radiosurgery
Radiofrequency thermocoagulation or rhizotomy
Effective, but risk of facial numbness and
Cornea
l insensitivity
Oturai (1996) Clin J Pain 12(4):311-5 [PubMed]
Invasive Surgical Techniques
Microvascular decompression (posterior fossa exploration)
Most effective and long lasting (duration of 10 years in 70% of cases)
Preferred over sterotactic radiosurgery
Risk of unilateral
Hearing Loss
in 5% of cases
Hai (2006) Neurol India 54(1):53-6 [PubMed]
Tronnier (2001) Neurosurgery 48(6): 1261-8 [PubMed]
Peripheral Nerve
field stimulation
Implanted device near
Peripheral Nerve
s to disrupt pain signals
Up to 75% pain improvement in observational studies
Sarica (2022) J Neurosurg 137(5): 1387-95 [PubMed]
Complications
Major Depression
and
Suicidality
(due to severity of pain and incapacity)
Course
Remission is typical for months-years (>=6 months in >50% of patients)
Multiple Sclerosis
is associated with a more refractory course (to medications, interventions)
References
Amaechi (2025) Am Fam Physician 111(5): 427-32 [PubMed]
Krafft (2008) Am Fam Physician 77(9):1291-6 [PubMed]
Kumar (1998) Postgrad Med 104(4):149-56 [PubMed]
Scrivani (2005) Oral Surg Oral Med Oral Pathol Oral Radiol Endod 100(5):527-38 [PubMed]
Zakrzewska (2016) Am Fam Physician 94(2): 133-5 [PubMed]
Type your search phrase here